Reaction
High-Grade B-Cell Lymphoma reporting signals
As of the last recalculation, High-Grade B-Cell Lymphoma appears in 186 FAERS reports alongside 9 co-occurring drug terms. The strongest observed disproportionality signal is AXICABTAGENE CILOLEUCEL (PRR 184.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Axicabtagene Ciloleucel | 15 | 184.9 | 185.2 |
| Etoposide | 45 | 90.0 | 90.1 |
| Doxorubicin | 48 | 80.9 | 80.9 |
| Bleomycin Sulfate | 7 | 78.8 | 78.8 |
| Bendamustine Hcl | 8 | 60.3 | 60.3 |
| Vincristine Sulfate | 14 | 57.7 | 57.8 |
| Gemcitabine | 16 | 49.6 | 49.7 |
| Ifosfamide | 9 | 49.2 | 49.2 |
| Polatuzumab Vedotin | 4 | 46.9 | 46.9 |